Department of Pathology
Brigham and Women's Hospital
A teaching Affliate of Harvard Medical School
 

Name and Present Position:

Lucian R. Chirieac, Associate Pathologist

Address:

Brigham and Women's Hospital, Department of Pathology, 75 Francis Street, Boston, MA 02115

Medical School (including school name, date and degree awarded):

1991 M.D., Carol Davila University of Medicine and Pharmacy, Bucharest
 

Graduate Medical Education (including dates and institution of internships, residencies, fellowships, etc.):

1991-1993 Intern in Orthopedic Surgery, Clinic of Orthopedic and Trauma Surgery, University Hospital, Bucharest
1991 Visiting Fellow in Orthopedic Surgery, Edouard Herriot Hospital, Lyon and Clinique Mutualiste de la Digonniere, Saint-Etienne
1995-1996 Postdoctoral Fellow in Pathology, University of Rochester, Rochester, NY
1996-2002 Resident in Pathology, Strong Memorial Hospital, University of Rochester, Rochester, NY
2002-2003 Chief Fellow in Selective Pathology, The University of Texas, M. D. Anderson Cancer Center, Houston, TX
2003-2004 Postdoctoral Fellow in Pathology, The University of Texas M. D. Anderson Cancer Center, Houston, TX

Certification:

2002 American Board of Pathology (Anatomic and Clinical Pathology)

Current Academic Appointment:

Assistant Professor of Pathology, Harvard Medical School, Boston, MA

Current Medical Staff Appointments:

Associate Pathologist, Brigham and Women's Hospital, Boston, MA
Dana-Farber/Harvard Cancer Center (DF/HCC) Lung Cancer Program, Boston, MA

Honors and Awards:

2007 Pulmonary Pathology Society Award for outstanding Pulmonary Pathology Presentation at the 2007 USCAP Meeting. San Diego, CA, 2007
2004 Stowell-Orbison Award of the United States and Canadian Academy of Pathology. USCAP Annual Meeting, Vancouver, Canada
2004 ASCO Foundation Merit Award of the American Society of Clinical Oncology. ASCO Annual Meeting, New Orleans, LA, June 2004
1997 Pathology Resident Award of the American Society of Clinical Pathologists and the College of American Pathologists for the Best Paper Presentation. Fall Meeting, Philadelphia, PA.

Selected Bibliography:

  • Richards W, Van Oss S, Glickman J, Chirieac L, Yeap B, Dong L, Gordon G, Mercer H, Gill K, Imrich A, Bueno R, Sugarbaker D. A microaliquoting technique for precise histological annotation and optimization of cell content in frozen tissue specimens. Biotech Histochem. 2007 Oct 3;:1-9.
  • Sholl LM, John Iafrate A, Chou YP, Wu MT, Goan YG, Su L, Huang YT, Christiani DC, Chirieac LR. Validation of chromogenic in situ hybridization for detection of EGFR copy number amplification in nonsmall cell lung carcinoma. Mod Pathol. 2007 Oct;20(10):1028-35.
  • Ji H, Ramsey MR, Hayes DN, Fan C, McNamara K, Kozlowski P, Torrice C, Wu MC, Shimamura T, Perera SA, Liang MC, Cai D, Naumov GN, Bao L, Contreras CM, Li D, Chen L, Krishnamurthy J, Koivunen J, Chirieac LR, Padera RF, Bronson RT, Lindeman NI, Christiani DC, Lin X, Shapiro GI, Janne PA, Johnson BE, Meyerson M, Kwiatkowski DJ, Castrillon DH, Bardeesy N, Sharpless NE, Wong KK. LKB1 modulates lung cancer differentiation and metastasis. Nature. 2007 Aug 16;448(7155):807-10.
  • Li D, Shimamura T, Ji H, Chen L, Haringsma HJ, McNamara K, Liang MC, Perera SA, Zaghlul S, Borgman CL, Kubo S, Takahashi M, Sun Y, Chirieac LR, Padera RF, Lindeman NI, Janne PA, Thomas RK, Meyerson ML, Eck MJ, Engelman JA, Shapiro GI, Wong KK. Bronchial and peripheral murine lung carcinomas induced by T790M-L858R mutant EGFR respond to HKI-272 and rapamycin combination therapy. Cancer Cell. 2007 Jul;12(1):81-93.
  • Freedman RA, Wirth LJ, Chirieac LR, Huang EC. Glioblastoma in a patient with early-stage tonsil cancer. J Clin Oncol. 2007 Jul 1;25(19):2848-50.
  • Finberg KE, Sequist LV, Joshi VA, Muzikansky A, Miller JM, Han M, Beheshti J, Chirieac LR, Mark EJ, Iafrate AJ. Mucinous differentiation correlates with absence of EGFR mutation and presence of KRAS mutation in lung adenocarcinomas with bronchioloalveolar features. J Mol Diagn. 2007 Jul;9(3):320-6.
  • Heist RS, Zhou W, Chirieac LR, Cogan-Drew T, Liu G, Su L, Neuberg D, Lynch TJ, Wain JC, Christiani DC. MDM2 polymorphism, survival, and histology in early-stage non-small-cell lung cancer. J Clin Oncol. 2007 Jun 1;25(16):2243-7.
  • Ji H, Wang Z, Perera SA, Li D, Liang MC, Zaghlul S, McNamara K, Chen L, Albert M, Sun Y, Al-Hashem R, Chirieac LR, Padera R, Bronson RT, homas RK, Garraway LA, Janne PA, Johnson BE, Chin L, Wong KK. Mutations in BRAF and KRAS converge on activation of the mitogen-activated protein kinase pathway in lung cancer mouse models. Cancer Res. 2007 May 15;67(10):4933-9.
  • Danan Li, Hongbin Ji, Sara Zaghlu, Kate McNamara, Shigeto Kubo,Masaya Takahashi, Lucian R. Chirieac, Robert Padera, Andrew M. Scott, Lloyd J. Old, George D. Demetri, Kwok-Kin Wong. Unique epitope recognition by anti-EGFR antibody 806 generates responses in genetically defined murine de novo EGFR mutant-dependent lung carcinomas. J. Clin. Invest, 2007 Jan: p. JCI30446.
  • Wu TT, Chirieac LR, Abraham SC, Krasinskas AM, Wang H, Rashid A, Correa AM, Hofstetter WL, Ajani JA, Swisher SG. Excellent Interobserver Agreement on Grading the Extent of Residual Carcinoma After Preoperative Chemoradiation in Esophageal and Esophagogastric Junction Carcinoma: A Reliable Predictor for Patient Outcome. Am J Surg Pathol. 2007 Jan;31(1):58-64.
  • Chirieac LR, Rice DC, Raymond AK. Epithelioid hemangioendothelioma in a patient with unusual involvement of the rib and intercostal lymph nodes. J Thorac Cardiovasc Surg. 2006 Dec;132(6):1488-9.
  • Chirieac LR, Trent JC, Steinert DM, Choi H, Yang Y, Zhang J, Patel SR, Benjamin RS, Raymond AK. Correlation of immunophenotype with progression-free survival in patients with gastrointestinal stromal tumors treated with imatinib mesylate. Cancer. 2006 Nov 1;107(9):2237-44.
  • Ettinger DS, Bepler G, Bueno R, Chang A, Chang JY, Chirieac LR, D'Amico TA, Demmy TL, Feigenberg SJ, Grannis FW Jr, Jahan T, Jahanzeb M, Kessinger A, Komaki R, Kris MG, Langer CJ, Le QT, Martins R, Otterson GA, Robert F, Sugarbaker DJ, Wood DE; National Comprehensive Cancer Network (NCCN). Non-small cell lung cancer clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2006 Jul;4(6):548-82.
  • Ji H, Li D, Chen L, Shimamura T, Kobayashi S, McNamara K, Mahmood U, Mitchell A, Sun Y, Al-Hashem R, Chirieac LR, Padera R, Bronson RT, Kim W, Janne PA, Shapiro GI, Tenen D, Johnson BE, Weissleder R, Sharpless NE, Wong KK. The impact of human EGFR kinase domain mutations on lung tumorigenesis and in vivo sensitivity to EGFR-targeted therapies. Cancer Cell. 2006 Jun;9(6):485-95.
  • Richards WG, Zellos L, Bueno R, Jaklitsch MT, Janne PA, Chirieac LR, Yeap BY, Dekkers RJ, Hartigan PM, Capalbo L, Sugarbaker DJ. Phase I to II study of pleurectomy/decortication and intraoperative intracavitary hyperthermic cisplatin lavage for mesothelioma. J Clin Oncol. 2006 Apr 1;24(10):1561-7.
  • Chirieac LR, Dekmezian RH, Ayala AG. Characterization of the myxoid variant of hibernoma. Ann Diagn Pathol. 2006 Apr;10(2):104-6.
  • National Comprehensive Cancer Network (NCCN) Non-Small Cell Lung Cancer Panel. Practice Guidelines in Oncology. Principles of Pathologic Review, Non-Small Cell Lung Cancer Guidelines version 2.2006, NCCN.
  • Lin Q, Lai R, Chirieac LR, Li C, Thomazy VA, Grammatikakis I, Rassidakis GZ, Zhang W, Fujio Y, Kunisada K, Hamilton SR, Amin HM. Constitutive activation of JAK3/STAT3 in colon carcinoma tumors and cell lines: inhibition of JAK3/STAT3 signaling induces apoptosis and cell cycle arrest of colon carcinoma cells. Am J Pathol. 2005 Oct;167(4):969-80.
  • Jackman D, Chirieac LR, Jänne P A. Bronchioloalveolar carcinoma: a review of the epidemiology, pathology, and treatment. Semin Respir Crit Care Med. 2005 Jun;26(3):342-52.
  • Swisher SG, Hofstetter W, Wu TT, Correa AM, Ajani JA, Komaki RR, Chirieac LR., Hunt KK, Liao Z, Phan A, Rice DC, Vaporciyan AA, Walsh GL, Roth J. Proposed revision of the pTNM esophageal cancer staging system to accommodate pathologic response (pP) following preoperative chemoradiation (CRT). Ann Surg. 2005 May;241(5):810-7; discussion 817-20.
  • Chirieac LR, Shen L, Catalano PJ, Issa JP, and Hamilton SR. Phenotype of microsatellite-stable colorectal carcinoma with CPG island methylation. Am J Surg Pathol. 2005 Apr;29(4):429-36.
  • Chirieac LR, Swisher SG, Ajani, Komaki RR, Correa AM, Rashid A, Hamilton SR and Wu T-T. Presence of signet-ring cell or mucinous histology after preoperative chemoradiation is associated with high probability of survival in patients with esophageal or esophagogastric junction adenocarcinoma. Clin Cancer Res. 2005 Mar 15;11(6):2229-36.
  • Chirieac LR, Swisher SG, Ajani, Komaki RR, Correa AM, Roth J, Rashid A, Hamilton SR and Wu T-T. Residual tumor status predicts long-term survival in esophageal cancer following preoperative chemoradiation and surgery, Cancer 2005; 103 (7): 1347-1355.
  • Chirieac DV*, Chirieac LR*, Corsetti JP, Cianci J, Bolognino M, Sparks CE and Sparks JD. Glucose- stimulated insulin secretion suppresses hepatic triglyceride-rich lipoprotein and apolipoprotein b production in vivo. Am J Physiol Endo 2000; 279: E1003-11. (*equal contribution)
  • Chirieac LR, Mexiletine. Ther Drug Monitor Toxicol. 1998; 5:115-119
  • Chirieac LR, Chirieac LI. Carbamazepine in Bipolar Disorder. Ther Drug Monitor Toxicol. 1997; 11:283-285